Repros Therapeutics (Nasdaq:RPRX) Soars on Reproductive Results

Repros Therapeutics (Nasdaq:RPRX) is a company which specializes in treating disorders related to reproduction, and after positive results from their latest animal trials were released, the company was rewarded with their share price skyrocketing over 36 percent and trading volume rising almost 80 times its normal levels over the last 3 months.

Proellex was the subject of the animal trials, where results revealed there was the probability they could produce effective and safe treatment for uterine fibroids and endometriosis.

Chief Executive Joseph S. Podolski said, "The animal data is impressive. If we can obtain agreement from the FDA to conduct a study of vaginally administered Proellex in the second quarter of 2011, we can be in a position to compare low dose oral administration to vaginal administration by year end."

Repros wanted to develop a vaginally-delivery system for Proellex when higher oral doses of the drug resulted in much higher levels of liver enzymes.

Repros Therapeutics closed Monday at $3.51, up $0.944, or 36.79 percent.